Royalty Report: Drugs, cardiac, Disease – Collection: 328142


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Drugs
  • cardiac
  • Disease
  • Therapeutic
  • Enzymes
  • Diagnostic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 328142

License Grant
The University grants
–  an exclusive license to make, have made, use, sell, offer to sell and import the Know-How in the Territory and within the Fields of Use; and,
–  an exclusive license of University’s Patent Rights, except for Patent Rights in University Case No. 2002.026H, in the Territory to make, have made, use, sell, offer to sell, and import any Licensed Products in the Fields of Use and to practice any Licensed Processes in the Fields of Use; and
–  an exclusive license of University’s Patent Rights in University Case No. 2002.026H in the Territory to make, have made, use, sell, offer to sell and import any Licensed Products in the Fields of Use and to practice any Licensed Process in the Fields of Use.
License Property
Licensor has rights to technology relating to expression profiling in the intact human heart and a method of treating heart failure with bucindolol.

Bucindolol means the beta-adrenergic–receptor antagonist having the chemical formula 2-{2-hydroxy-
3{{2-(3-indolyl)-1,1-dimethylethyl}amino}propoxy}-benzonitrile hydrochloride, and its racemates, isomers, prodrugs, active metabolites, analogs and any pharmaceutically acceptable salt or complex thereof, and diagnostics used in connection with its prescription.

Bucindolol Invention shall mean an Invention relating solely to the use of Bucindolol as a therapeutic or as a diagnostic used solely in connection with the development of Bucindolol.

Patents are titled
Expression Profiling in the Intact Human Heart,
Methods for Treating Heart Failure with Bucindolol Based on Genetic Targeting of the Alpha-le Adrenergic
Methods for Treating Heart Failure with Bucindolol Based on Genetic Targeting of the Beta-1 Adrenergic
     Receptor, and,
Methods for Treatment with Bucindolol Based on Genetic Targeting.

Field of Use
Fields of use is all fields.

Licensee is focused on developing and commercializing genetically-targeted therapies for heart failure and other cardiovascular diseases.

IPSCIO Record ID: 152350

License Grant
Licensor hereby assigns all of its rights under the Knoll Agreement to Licensee, and Licensee hereby assumes and agrees to perform, pay and discharge all of Licensees and Licensors obligations under the Knoll Agreement arising after the date of this Agreement, as such relate to the development or commercialization of Bucindolol or the Product in the Knoll Territory.
License Property
Product means Bucindolol and any finished product containing Bucindolol as the active ingredient.

Bucindolol means the compound Benzonitrile, 2-[2-hydroxy-3-[[2-(1H-indol-3-yl)-1,1-imethylethyl]amino]propoxy]-, monohydrochloride, also known under the trademark 'BEXTRA'.

Bucindolol Intellectual Property means the Trademarks and any patents, patent applications, copyrights, know-how, processes, formulae, data (including, but not limited to, preclinical, clinical, and marketing data) and trade secrets relating to the manufacture, development, commercialization or use of Bucindolol including any Improvement made or acquired by Licensor during the term of this Agreement.

BEAT means the Bucindolol Evaluation in Acute Myocardial Infarction Trial being conducted by Knoll.

BEST means the 'Beat-blocker Evaluation of Survival Trial' being conducted by the National Institutes of Health and the Veterans Administration, evaluating the use of Bucindolol in treating patients with congestive heart failure.

Trademark means the registered trademark BEXTRA(R), any other trademark, trade name or service mark used as a product identifier for Bucindolol and any variations thereof, in each case, whether or not registered.

Field of Use
'Field' means use of Bucindolol as a pharmaceutical therapy for congestive heart failure and/or left ventricular dysfunction.

IPSCIO Record ID: 240577

License Grant
Licensor grants the exclusive right and license under the Intellectual Property and Know How to make, have made, use, lease, sublicense and sell the Licensed Products, and to practice the Licensed Processes in the Territory for the Field of Use.
License Property
Licensor is the owner of certain University of Colorado intellectual property, embodied in inventions, patent rights, patents, patent applications, copyrights or proprietary Know-How (as later defined herein and referred to collectively as Intellectual Property Rights, related to six separate invention disclosures.

The invention disclosures are Angiotention-Converting Enzyme Genetic Variant Screen; Transgenic Mouse Over-Expressing the Human Beta-1 Adrenergic Receptor A Screening Tool for New Heart Failure Therapeutic Agents; Transgenic Model for Heart Failure; Method for ldentifying Adrenergic Receptor Antagonists Having Good Tolerability; Diagnosis and Treatment of Myocardial Failure; and, Method of Treating Heart Failure Using Enoximone and Metoprolol.

Field of Use
The Field of Use shall mean human heart disease diagnosis, prevention and therapy.

IPSCIO Record ID: 240469

License Grant
This amendments revises the intellectual property, royalties and identifies potential options to be exercised.  This agreement is for enoximone property and processes.
License Property
Enoximone is a small organic molecule that exhibits highly selective inhibition of type-III phosphodiesterase, or PDE-III, an enzyme that is present in the heart and plays an important regulatory role in cardiac function.

The licensed property is Angiotensin-converting enzyme genetic variant screens; Transgenic model and treatment for heart disease; Transgenic Model for Heart Failure; Method for identifying adrenergic receptor antagonists having good tolerability; Diagnosis and treatment of myocardial failure; Method of treating heart failure; Inhibition of HDAC as a treatment for cardiac hypertrophy; and, Quantitative analysis of closely related protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry.

Field of Use
Licensee is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders.

IPSCIO Record ID: 273380

License Grant
The University, with permissions as applicable, grant an exclusive, sublicensable license for the field of Use in the Territory to
—  practice under the Patent Rights
—  make, have made, use, lease, import, export and/or sell Licensed Products,
—  sell, use and/or practice Licensed Services.

The University grants a non-exclusive license to use Know-how for the Field of Use in the territory to
—  make, have made, use, lease and/or sell Licensed Products
—  sell, use and/or practice Licensed Services.

License Property
The University has rights to patents titles Reactive Oxygen Generating Enzyme and Inhibitor with Nitric Oxide Bioactivity and Uses Thereof, and, Composition for the Treatment and Prevention of Heart Disease and Methods of Using the Same.

The Phase II candidate and all other drugs in the portfolio are designed to correct nitric oxide and redox disequilibrium in the failing heart and cardiovascular system. All have a dual mechanism of action of inhibiting the creation of reactive oxygen radicals and concurrently providing nitric oxide in the failing heart. The therapeutic target is the ryanodine receptor, the ion channel in the heart that provides the calcium necessary for the heart to beat. The investigational drugs are believed to improve calcium cycling in the heart by acting on the ryanodine receptor to significantly improve the efficiency of heart contractility.

Field of Use
The field of use means all therapeutic uses for allopurinol, oxypurinol, ptcein-6-aldehyde and mixtures thereof, that are provided with a nitrate group thereon, as well as therapeutic uses for any combinations of these agents with nitrates or other NO donors.

The drug portfolio is to develop and commercialize certain of Licensee's proprietary cardiovascular drugs to treat heart failure.

IPSCIO Record ID: 240578

License Grant
The University grants a worldwide, exclusive license under Licensed Subject matter to discover, research, develop, make, have made, use offer for sale, sell and import Licensed Products and Identified Products for use within Licensed Field.
License Property
Licensed Product means any compound, assay, method, reagent, technology, product or service comprising Licensed Subject Matter.

Licensed Subject Matter means inventions, discoveries, assays and processes covered by Patent Rights and/or Technology Rights within Licensed Field.

The patents are for Methods and Compositions Relating to Muscle Selective Calcineurin Interacting Protein (MCIP).

Field of Use
Licensed field means treatment, prevention, diagnosis and/or prognosis of cardiac hypertrophy, heart disease and heart failure; and determination of predisposition to cardiac hypertrophy, heart disease and heart failure.

IPSCIO Record ID: 263954

License Grant
The German Licensor grants an exclusive right and license in the Territory, under Licensors Technology, for all Pharmaceutical Uses, with the right to grant sublicenses, to research, develop, modify and improve Compound and Product;  apply for and obtain Regulatory Approvals; and use, import/export, market, offer to sell and sell, Product and Compound.
License Property
The Compound means the endothelin receptor antagonist compound identified as BSF 208075 (ambrisentan) and the chemical name, (+)-(S)-2-(4,6-Dimethyl-pyrimidin-2-yloxy)-3-methoxy-3,3- diphenyl propionic acid, its racemates, isomers, Prodrugs, active metabolites and any pharmaceutically acceptable salt or complex thereof, in its current and any other formulation.
Field of Use
The license is for any pharmaceutical use.  The clinical study of the compound is for pulmonary arterial hypertension, Chronic Renal Failure and Chronic Heart Failure.

IPSCIO Record ID: 178134

License Grant
Licensor grants the exclusive right in the Territory to bucindolol product improvements (e.g., sustained release formulation, improved or new indications, formulations and strengths), contingent upon Licensee reimbursing Licensor for costs relating to clinical trials and other tests conducted primarily for benefit of the Territory and 1/3 of all other development costs which have a worldwide benefit, including any previous product improvement development costs incurred by Licensor.
License Property
Bucindolol is a drug currently in Phase III clinical trials for congestive heart failure ('CHF' or 'heart failure').
Field of Use
This agreement pertains to the drug industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.